Verici Dx Plc (VRCI) AI Stock Analysis

• Market Cap: £9.46M
• Dividend Yield: N/A
• Average Volume (3M): 6.85M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.03
• Revenue Growth: -57.03%
• EPS Growth: -15.71%
• Country: UK
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,513,394,200
• 10 Day Avg. Volume: 9,044,876
• 30 Day Avg. Volume: 6,845,005
• PEG Ratio: 0.04
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 3.38
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: 0.50p ▼(-28.57% Downside)

The overall stock score is primarily influenced by financial performance challenges, including ongoing net losses and negative cash flows. Technical analysis indicates a neutral market momentum, while valuation concerns are highlighted by a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates expanding adoption of Verici Dx's diagnostic tests, suggesting a strengthening market position in the transplant diagnostics sector.

Low Leverage

A low debt-to-equity ratio reflects a conservative capital structure, providing financial stability and flexibility for future growth opportunities.

Innovative Product Offering

The focus on innovative genomic tests for transplant diagnostics positions Verici Dx as a leader in precision medicine, offering a competitive advantage in a niche market.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, reflected by negative EBIT and net income, may hinder long-term financial sustainability and investment capacity.

Negative Cash Flow

Persistent negative cash flow from operations suggests reliance on external financing, which could limit financial flexibility and increase risk.

Net Losses

Continued net losses impact return metrics and could strain resources, necessitating strategic adjustments to achieve sustainable profitability.

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

How the Company Makes Money

Verici Dx generates revenue primarily through the sale of its diagnostic tests to hospitals, transplant centers, and healthcare providers. The company benefits from a fee-for-service model, where it charges healthcare institutions for each test performed. Additionally, Verici Dx may explore partnerships and collaborations with pharmaceutical companies and research institutions, which can provide further revenue opportunities through joint ventures, research grants, or co-development agreements. The expansion of its test offerings and the establishment of new relationships within the healthcare ecosystem are significant factors contributing to its earnings.

Verici Dx Plc Financial Statement Overview

Summary

Verici Dx Plc is experiencing revenue growth but continues to face profitability challenges, with ongoing net losses impacting return metrics. The balance sheet remains stable with low leverage, although cash flow issues persist due to negative operating cash flows, indicating the need for careful financial management and potentially further external financing.

Income Statement

Verici Dx Plc has shown a significant increase in total revenue from 2023 to 2024, indicating positive revenue growth. However, the company has consistently reported negative EBIT and net income figures, reflecting ongoing losses. The gross profit margin stands at 100% due to the absence of cost of goods sold, but negative net profit and EBIT margins highlight profitability challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with a low debt-to-equity ratio, suggesting a conservative capital structure. However, the return on equity is negative due to net losses, which is a concern. The equity ratio indicates that a significant portion of the company's assets is financed by equity, which is a positive sign of financial stability.

Cash Flow

The cash flow statement reveals negative operating and free cash flow, indicating cash outflows from core operations. Financing activities have provided substantial cash inflows, suggesting reliance on external financing. The operating cash flow to net income ratio is negative, reinforcing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.34M	1.01M	0.00	0.00	0.00
Gross Profit	3.34M	1.01M	0.00	0.00	0.00
EBITDA	-5.15M	-7.88M	-10.50M	-7.15M	-2.10M
Net Income	-5.87M	-8.73M	-11.36M	-8.33M	-7.10M
Balance Sheet
Total Assets	7.49M	7.44M	14.30M	13.79M	20.31M
Cash, Cash Equivalents and Short-Term Investments	4.06M	2.65M	9.80M	10.34M	17.75M
Total Debt	371.00K	540.00K	700.00K	0.00	73.55K
Total Liabilities	2.23M	3.88M	2.80M	1.80M	681.89K
Stockholders Equity	5.26M	3.56M	11.51M	11.98M	19.62M
Cash Flow
Free Cash Flow	-6.21M	-7.39M	-11.38M	-7.30M	-1.32M
Operating Cash Flow	-6.02M	-7.16M	-10.07M	-6.34M	-1.28M
Investing Cash Flow	61.00K	-231.00K	-1.31M	-965.86K	-237.16K
Financing Cash Flow	7.32M	-27.00K	12.67M	-73.55K	26.75M

Verici Dx Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Negative. The current price of 0.7 is below the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.73, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.53 is Neutral, neither overbought nor oversold. The STOCH value of 19.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VRCI.

Verici Dx Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	£17.58M	―	-90.48%	―	37.39%	-126.19%
BSFA	56 Neutral	£2.78M	-1.54	-46.41%	―	-64.18%	12.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	51 Neutral	£10.04M	―	―	―	125.37%	22.47%
VRCI	46 Neutral	£9.46M	-0.26	-122.54%	―	-57.03%	-15.71%
PRM	40 Underperform	£5.92M	-1.56	―	―	12.19%	18.12%
GENI	39 Underperform	£8.18M	-1.23	-181.41%	―	12.12%	54.24%

Verici Dx Plc Corporate Events

Verici Dx Achieves Successful CAP Accreditation Audit

Verici Dx Plc has successfully completed its second biennial CAP accreditation audit for its clinical laboratory, demonstrating its commitment to maintaining high standards in clinical laboratory practices. This accreditation ensures that Verici Dx can consistently provide reliable test results, reinforcing its position as a trusted partner to clinicians and enhancing personalized care for kidney transplant patients.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Expands Reach with Prime Health Services Agreement

Verici Dx Plc has entered into a Provider Participation Agreement with Prime Health Services, a leading US-based healthcare technology company with a vast Preferred Provider Organization network. This agreement is a significant step for Verici Dx, as it expands its commercial reach and patient network, enhancing its coverage from private payors and potentially increasing its market presence in the healthcare diagnostics sector.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Achieves ISO 27001 Audit Success, Enhancing Industry Trust

Verici Dx Plc has successfully completed its annual ISO 27001:2022 surveillance audit, reaffirming its commitment to data privacy and security. This achievement strengthens its reputation as a trusted partner in the organ transplant diagnostics industry, ensuring compliance with global standards and maintaining stakeholder confidence.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Plc Revises and Expands Share Options to Align with Market Conditions

Verici Dx Plc has announced a revision of its share options, adjusting the exercise price of existing options and granting new options to directors, employees, and consultants. This move aims to realign incentives with current market conditions and ensure alignment between the interests of the company’s stakeholders and its leadership, following a decrease in share price and recent fundraising activities.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Appoints Aubrey Powell as Non-executive Director

Verici Dx plc has announced the appointment of Aubrey Powell as a Non-executive Director, replacing Dr. Erik Lium who has stepped down. Aubrey Powell brings over 30 years of experience in investment banking and corporate finance, with a strong focus on healthcare and life sciences. His expertise is expected to be invaluable as Verici Dx enters a pivotal stage of growth, enhancing its strategic direction and corporate governance.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Expands Tutivia™ Test Adoption with New Transplant Centers

Verici Dx Plc has reported significant progress in the commercial adoption of its Tutivia™ test, with a 19% increase in ordering clinicians and the onboarding of nine new transplant centers in Q3, now covering 16% of annual transplants in the US. The company has strengthened its commercial team with new hires, anticipating volume growth from Q4, and remains on track to meet market expectations for the year.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Expands Tutivia™ Test Adoption with New Transplant Centers

Verici Dx Plc has announced significant progress in the adoption of its Tutivia™ test, aimed at detecting acute rejection in transplant patients. The company has onboarded nine new transplant centers in Q3, bringing the total to 30 centers, which account for 16% of annual transplants in the US. Additionally, there has been a 19% increase in ordering clinicians, indicating strong commercial momentum. The company has also expanded its commercial team with new senior sales hires and a Director of Clinical Partnerships, positioning itself to meet market expectations for the full year.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Reports First Revenues and Expansion Plans for 2025

Verici Dx has reported significant commercial progress in the first half of 2025, with the first revenues from their lead product, Tutivia™, a test for acute rejection post-transplant. The company has raised £6.35m to support revenue scale-up, extending their cash runway into H2 2026. Tutivia™ has attained Medicare coverage, facilitating increased adoption across US transplant centers. The company is poised for growth with expanded commercial operations and expects significant acceleration in testing volumes in H2 2025 and beyond.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.